This study tests a medicine called ianalumab, given by injections, to see how well it works and how safe it is for people with autoimmune diseases like rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). The study compares two ways of giving the medicine: one injection of 300 mg in a 2 mL auto-injector (AI) and two injections of 150 mg in 1 mL pre-filled syringes (PFS). There are two main parts: the first lasts from Week 0 to Week 24, and the second is an optional extended period until Week 72. After that, there is a follow-up period for safety checks. The study involves visits and tests to ensure the medicine's safety and to see how it works in the body. Participants must be adults aged 18-70 with active disease and meet certain health criteria. Women who can become pregnant must use effective birth control.

• The study lasts up to 88 weeks, with an optional extended period.
• Participants receive monthly injections and undergo regular check-ups.
• Informed consent is required, and participants are compensated for their time.